Literature DB >> 29787819

Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups.

Corinna Lang-Schwarz1, Balint Melcher2, Franziska Haumaier2, Klaus Lang-Schwarz3, Thomas Rupprecht4, Michael Vieth2, William Sterlacci2.   

Abstract

Tumor budding is an independent prognostic factor in colorectal cancer (CRC) and has recently been well defined by the International Concensus Conference on Tumor Budding (ITBCC). Tumor-infiltrating lymphocytes (TILs) are also an issue in different human cancers and correlate with prognosis in CRC. Here we evaluate the combination of budding and TILs in CRC with regard to prognosis. Hematoxylin and eosin (H&E)-stained slides of 501 CRC patients, diagnosed between 2005 and 2010, were reevaluated for tumor budding according to the ITBCC criteria. Low (n = 331) was compared to intermediate/high budding (n = 170). The percentage of TILs was also assessed, and the following four groups were established: low budding + TILs >5% (n = 162), low budding + TILS ≤5% (n = 169), high budding + TILS >5% (n = 68), high budding + TILs ≤5% (n = 93). The combination of both markers revealed highly significant differences in overall survival (OS) between the four groups (P = .001). The low budding/>5% TILs group showed longest OS, followed by high budding/>5% TILs cases, followed by tumors with low budding/≤5% TILs. OS was worst for the high budding/≤ 5% TILs group. The combined score also correlated with T, N, M, L, Vstaging, development of disease relapse and distant metastasis. Our study shows that - even in the age of molecular pathology - it is still important to pay special attention to tumor morphology for additional information on tumor behavior and prognosis. Combining different morphological parameters of tumor and tumor environment can help to further subdivide CRC into new prognostic groups.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Budding; Colorectal cancer; Prognosis; Subgroups; Tumor- infiltrating lymphocytes (TILs)

Mesh:

Year:  2018        PMID: 29787819     DOI: 10.1016/j.humpath.2018.05.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

2.  Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists.

Authors:  Corinna Lang-Schwarz; Balint Melcher; Theresa Dregelies; Zahra Norouzzadeh; Stefanie Rund-Küffner; Klaus Lang-Schwarz; Michael Vieth; William Sterlacci
Journal:  Int J Colorectal Dis       Date:  2021-03-20       Impact factor: 2.571

3.  A classification based on tumor budding and immune score for patients with hepatocellular carcinoma.

Authors:  Li Wei; Zhang Delin; Yuan Kefei; Wu Hong; Huang Jiwei; Zhang Yange
Journal:  Oncoimmunology       Date:  2019-11-07       Impact factor: 8.110

4.  High CFP score indicates poor prognosis and chemoradiotherapy response in LARC patients.

Authors:  Siyi Lu; Zhenzhen Liu; Bingyan Wang; Fei Li; Yan Meng; Junwei Wang; Yuxia Wang; Hao Wang; Xin Zhou; Wei Fu
Journal:  Cancer Cell Int       Date:  2021-04-13       Impact factor: 5.722

Review 5.  Intraepithelial tumour infiltrating lymphocytes are associated with absence of tumour budding and immature/myxoid desmoplastic reaction, and with better recurrence-free survival in stages I-III colorectal cancer.

Authors:  I A González; P S Bauer; J Liu; D Chatterjee
Journal:  Histopathology       Date:  2020-09-14       Impact factor: 5.087

6.  Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer.

Authors:  Kenji Fujiyoshi; Juha P Väyrynen; Jennifer Borowsky; David J Papke; Kota Arima; Koichiro Haruki; Junko Kishikawa; Naohiko Akimoto; Tomotaka Ugai; Mai Chan Lau; Simeng Gu; Shanshan Shi; Melissa Zhao; Annacarolina Fabiana Lucia Da Silva; Tyler S Twombly; Hongmei Nan; Jeffrey A Meyerhardt; Mingyang Song; Xuehong Zhang; Kana Wu; Andrew T Chan; Charles S Fuchs; Jochen K Lennerz; Marios Giannakis; Jonathan A Nowak; Shuji Ogino
Journal:  EBioMedicine       Date:  2020-07-08       Impact factor: 8.143

7.  An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.

Authors:  Koichiro Haruki; Keisuke Kosumi; Peilong Li; Kota Arima; Juha P Väyrynen; Mai Chan Lau; Tyler S Twombly; Tsuyoshi Hamada; Jonathan N Glickman; Kenji Fujiyoshi; Yang Chen; Chunxia Du; Chunguang Guo; Sara A Väyrynen; Andressa Dias Costa; Mingyang Song; Andrew T Chan; Jeffrey A Meyerhardt; Reiko Nishihara; Charles S Fuchs; Li Liu; Xuehong Zhang; Kana Wu; Marios Giannakis; Jonathan A Nowak; Shuji Ogino
Journal:  Br J Cancer       Date:  2020-03-11       Impact factor: 7.640

8.  Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists.

Authors:  Corinna Lang-Schwarz; Balint Melcher; Arndt Hartmann; Simone Bertz; Theresa Dregelies; Klaus Lang-Schwarz; Michael Vieth; William Sterlacci
Journal:  Int J Colorectal Dis       Date:  2021-06-25       Impact factor: 2.571

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.